Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

NCT02721888 on ClinicalTrials.gov · last registry update 2026-02-06

Stopped early, having planned 127 participants. Completed 2 October 2019. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Centre Hospitalier Universitaire Dijon
Sponsor type: Other
Enrollment: 127
Started: 2012-07-10
Primary completion: 2019-10-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.